Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $19.41 -1.87%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
Oppenheimer analyst Jay Olson raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $23.00 (from $20.00) while maintaining a Perform rating.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $220 at BMO Capital
- Neurocrine Bio. (NBIX) PT Lowered to $150 at BMO Capital
- LPL Financial Holdings (LPLA) PT Lowered to $356 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
